Stocks · News reference
Filed: 2026-08-03 AccNo: 0001193125-26-330568 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
Read original at benzingaORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees as inducement for employment. The grants were approved by the Compensation Committee and comply with Nasdaq Rule 5635(c)(4). The company continues development of its clinical-stage oncology candidates including rinzimetostat for prostate cancer and enozertinib for NSCLC.
Read original at globenewswire-incORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share
Read original at benzinga